![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AeroClean Technologies Inc | NASDAQ:AERC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.40 | 3.06 | 3.48 | 0 | 01:00:00 |
“FDA clearance of our Pūrgo™ technology’s ability to eliminate SARs-CoV-2 is an incredible milestone and provides the expected expansion of scope that all of our testing has indicated,” said Jason DiBona, Chief Executive Officer of AeroClean. “Our team is dedicated to improving indoor air quality through the creation of long-term, health-focused solutions, and this latest indication validates the significant strength of our Pūrgo™ air sanitization device. We are currently completing additional testing to determine the efficacy of Pūrgo’s™ ability to remove other airborne microorganisms such as RSV and Influenza. We hope to see the preliminary results shortly.”Mr. DiBona added, “Its widely known that we are experiencing a ‘tripledemic’, composed of Influenza, RSV, and SARs-CoV-2, that has swept the United States in recent weeks. With the especially high impact these illnesses have had on the public, and particularly the country’s pediatric wards, Pūrgo™ is an essential tool that can be used to help create safer indoor environments.” AeroClean’s Pūrgo™ air purifier is classified as a Class II Medical Device and utilizes clinical-grade HEPA filtration and germicidal UV-C LED air sanitization technology, proven to eliminate 99.99% of harmful airborne microorganisms, including bacteria, fungi, and viruses. As previously announced, independent laboratory testing has proven Pūrgo™ is effective at reducing the viral concentration of the SARS-CoV-2 the virus that causes COVID-19. Testing was completed on the Omicron variant which the CDC identifies as one of the most dominant variants currently circulating in the United States.
The independent testing conditions simulated real world environments, with room sized chambers. The independent testing was conducted by Innovative Bioanalysis laboratories to test the efficacy of the AeroClean Pūrgo™ units against SARS-CoV-2, the Omicron variant, during a 60-minute test run. The AeroClean Pūrgo™ unit demonstrated a significant and quantifiable reduction in the recoverable active Omicron variant of SARS-CoV-2 in indoor air space, as shown by a 94.17% gross reduction after 30 minutes, and a 99.998% gross reduction in the highly transmissible airborne virus after 60 minutes in a room-sized chamber.
AeroClean’s efficacy test report on the Omicron Variant of SARS-CoV-2 can be available on request by sending an email to info@aeroclean.com.
For more information about AeroClean technology and Pūrgo™ solutions, visit: www.AeroClean.com.
About AeroClean TechnologiesAeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—by improving indoor air quality. Our air hygiene product, Pūrgo™ (pure-go), is an FDA 510(k) cleared, Class II medical device that provides continuous air filtration, sanitization and supplemental ventilation solutions with technology that can be applied in any indoor space - including in hospitals, offices, and even in elevators. Pūrgo™ products feature SteriDuct™, a proprietary germicidal technology developed by our best-in-class aerospace engineers, medical scientists and innovators that work to eradicate viral, fungal, and bacterial airborne microorganisms. Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops. Learn more at aeroclean.com.
Media ContactDrew Tybusdrew@oakpr.com
Investor Relations ContactsRyan TylerChief Financial Officer, AeroCleanRTyler@AeroClean.com
Rob KellyMATTIO Communicationsaeroclean@mattio.com
1 Year AeroClean Technologies Chart |
1 Month AeroClean Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions